Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Read more
Sign In
June 16, 202110:41 AM PDTLast Updated 2 months ago
Healthcare & Pharmaceuticals
Novartis prostate cancer drug receives U.S. FDA breakthrough designation

2 minute read
The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo
ZURICH, June 16 (Reuters) - Swiss drugmaker Novartis AG (NOVN.S) has received breakthrough therapy designation from the U.S. Food and Drug Administration for an experimental treatment for advanced castration-resistant prostate cancer, the company said on Wednesday.
Men with a deadly form of prostate cancer that has spread and who were not helped by other treatments on average survived four months longer after getting Novartis’ Lu-PSMA-617 - a tumour-targeting radiation therapy - than those who received standard care, data from a clinical trial released earlier in June showed.
The therapy attaches a radioactive isotope, lutetium-177, with a half-life of less than seven days, to a small molecule drug, PSMA-617, that binds to an antigen expressed in large amounts by prostate cancer cells. It aims to kill cancer cells in a targeted way while limiting damage to surrounding, healthy cells.
The FDA breakthrough designation is used to help expedite development and review of therapies that demonstrate the potential to be a substantial improvement over available treatments.
Novartis, which acquired the therapy with its $2.1 billion purchase of Endocyte three years ago, has a growing portfolio of radioligand medicines that includes already approved cancer therapy Lutathera.
Prostate cancer can often be treated via surgery, radiation therapy or through hormone therapy that stops production of tumour-driving testosterone.
Metastatic castration-resistant prostate cancer, however, has failed to respond to such hormone treatment, making it difficult to treat - and a potentially lucrative market. Novartis has forecast eventual Lu-PSMA-617 annual sales topping $1 billion.
Reporting by Brenna Hughes Neghaiwi Editing by Mark Heinrich
Our Standards: The Thomson Reuters Trust Principles.
More from Reuters
Play video on original page

Read Next
Asia Pacific
Tokyo doctor at the crossroads of a COVID-19 crisis and a quiet Olympics
4:58 AM PDT
Asia Pacific
Japan warns of unprecedented COVID spread as cases hit record in Olympic host city
4:57 AM PDT
Asia Pacific
Vietnam to half quarantine time for fully vaccinated visitors
4:55 AM PDT
Asia Pacific
Indonesia passes grim milestone of over 100,000 COVID-19 deaths
4:52 AM PDT

Sign up for our newsletter
Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Healthcare & Pharmaceuticals
Healthcare & Pharmaceuticals · 2:29 AM PDT
China reports most new COVID-19 cases since January amid Delta surge
China reported on Wednesday the most new locally transmitted COVID-19 cases since January as some cities stepped up restrictions, cut flights and increased testing to get to grips with an outbreak driven mainly by the Delta variant.
Healthcare & Pharmaceuticals
Japan warns of unprecedented COVID spread as cases hit record in Olympic host city
4:57 AM PDT
Healthcare & Pharmaceuticals
S.Korea COVID-19 count spikes amid vacations, spread of new variants
August 3, 2021
Healthcare & Pharmaceuticals
Macau begins COVID-19 tests and shuts some entertainment venues, casino stocks fall
August 3, 2021
Healthcare & Pharmaceuticals
Man in his 20s becomes one of Australia's youngest COVID-19 deaths
12:37 AM PDT
About Reuters
About Reuters
Reuters News Agency
Brand Attribution Guidelines
Reuters Leadership
Reuters Fact Check
Reuters Diversity Report
Stay Informed
Download the App
Information you can trust
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Follow Us
Thomson Reuters Products
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Refinitiv Products
Information, analytics and exclusive news on financial markets - delivered in an intuitive desktop and mobile interface.
Refinitiv Data Platform
Access to real-time, reference, and non-real time data in the cloud to power your enterprise.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
Advertise With Us
Advertising Guidelines
Terms of Use
Site Feedback

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All rights reserved